• Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
  
• Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
  

PubMed=25428917; DOI=10.18632/oncotarget.2703; PMCID=PMC4381591
Jennifer L. Bishop, Alexander Sio, Arkhjamil Angeles, Morgan E. Roberts, Arun A. Azad, Kim N. Chi, Amina Zoubeidi;
PD-L1 is highly expressed in enzalutamide resistant prostate cancer.
Oncotarget 6:234-242(2015)

PubMed=25634993; DOI=10.1158/1078-0432.CCR-14-1108
Yoshiaki Yamamoto, Yohann Loriot, Eliana Beraldi, Fan Zhang, Alexander W. Wyatt, Nader Al Nakouzi, Fan Mo, Tian-Yuan Zhou, Youngsoo Kim, Brett P. Monia, A. Robert MacLeod ...Show all 16 authors... , Ladan Fazli, Yu-Zhuo Wang, Colin C. Collins, Amina Zoubeidi, Martin E. Gleave; Show fewer authors
Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Clin. Cancer Res. 21:1675-1687(2015)